Cited 6 time in
Generation of Fel d 1 chain 2 genome-edited cats by CRISPR-Cas9 system
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Sang Ryeul | - |
| dc.contributor.author | Lee, Kyung-Lim | - |
| dc.contributor.author | Song, Seok-Hwan | - |
| dc.contributor.author | Joo, Myeong-Don | - |
| dc.contributor.author | Lee, Seo-Hyun | - |
| dc.contributor.author | Kang, Ji-Su | - |
| dc.contributor.author | Kang, Seon-Min | - |
| dc.contributor.author | Idrees, Muhammad | - |
| dc.contributor.author | Kim, Jae-Wook | - |
| dc.contributor.author | Kong, Il-Keun | - |
| dc.date.accessioned | 2024-03-24T02:00:30Z | - |
| dc.date.available | 2024-03-24T02:00:30Z | - |
| dc.date.issued | 2024-02 | - |
| dc.identifier.issn | 2045-2322 | - |
| dc.identifier.issn | 2045-2322 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/69975 | - |
| dc.description.abstract | Allergens from domestic cats (Felis catus) cause allergy-related health problems worldwide. Fel d 1 is a major allergen that causes severe allergic reactions in humans, including rhinitis, conjunctivitis, and life-threatening asthma. Therefore, patients with cat allergies anticipate hypoallergenic cats. We successfully generated Fel d 1 chain 2 (CH2) genome-edited cats using the CRISPR-Cas9 system in this study. T7 endonuclease 1 assay and Sanger sequencing were used to confirm the mutation in CH2 genome-edited cats. Fel d 1 level in CH2 genome-edited cats were assessed by enzyme-linked immunosorbent assay (ELISA). Remarkably, ELISA showed that the level of Fel d 1 in the CH2 homozygous genome-edited cat (Name: Alsik) was extremely low compared with that in wild type domestic cats and could be hypoallergenic cats. Additionally, we successfully cloned the CH2 homozygous genome-edited cat using cytoplasm injection clone technology. The cloned CH2 homozygous genome-edited cat was verified using microsatellite analysis. Creating hypoallergenic cats using the CRISPR-Cas9 system is a significant step forward because these cats can safely approach allergic patients. © The Author(s) 2024. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Nature Publishing Group | - |
| dc.title | Generation of Fel d 1 chain 2 genome-edited cats by CRISPR-Cas9 system | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1038/s41598-024-55464-0 | - |
| dc.identifier.scopusid | 2-s2.0-85186322034 | - |
| dc.identifier.wosid | 001179204200040 | - |
| dc.identifier.bibliographicCitation | Scientific Reports, v.14, no.1 | - |
| dc.citation.title | Scientific Reports | - |
| dc.citation.volume | 14 | - |
| dc.citation.number | 1 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
| dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
| dc.subject.keywordPlus | MAJOR ALLERGEN | - |
| dc.subject.keywordPlus | DOMESTIC CAT | - |
| dc.subject.keywordPlus | D-I | - |
| dc.subject.keywordPlus | CRISPR/CAS9 | - |
| dc.subject.keywordPlus | DIAGNOSTICS | - |
| dc.subject.keywordPlus | EFFICIENCY | - |
| dc.subject.keywordPlus | EMBRYOS | - |
| dc.subject.keywordAuthor | Allergen | - |
| dc.subject.keywordAuthor | CH2 | - |
| dc.subject.keywordAuthor | CRISPR-Cas9 | - |
| dc.subject.keywordAuthor | Fel d 1 | - |
| dc.subject.keywordAuthor | Genome-edited cats | - |
| dc.subject.keywordAuthor | Hypoallergenic cats | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
